Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hypogonadism 4Eunuchism 2Testicular Neoplasms 1Prostatic Neoplasms 1Prostate Cancer Recurrent 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Klinefelter Syndrome 1Infertility 1Fatigue Syndrome, Chronic 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 277Prednisone 236enzalutamide 175Leuprolide 172Radiotherapy 164Abiraterone Acetate 153Magnetic Resonance Spectroscopy 147bicalutamide 137Goserelin 134Androgen Antagonists 111Radiosurgery 101acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 100apalutamide 78abiraterone 75gallium 68 PSMA-11 74Specimen Handling 67Gonadotropin-Releasing Hormone 58darolutamide 56Radiation 56Triptorelin Pamoate 53cabazitaxel 49Zoledronic Acid 49pembrolizumab 48Radiotherapy, Intensity-Modulated 47Flutamide 47Brachytherapy 47luprolide acetate gel depot 46Standard of Care 45Carboplatin 44Estramustine 43

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Neoplasms × testosterone undecanoate × Clear all
NCT05081193 2025-09-22

Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
15 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡